Fuzuloparib ± Apatinib Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer
Fuzuloparib with or without apatinib provided superior PFS benefit vs chemotherapy in HER2– metastatic breast cancer harboring germline BRCA1/2 mutations.
Fuzuloparib with or without apatinib provided superior PFS benefit vs chemotherapy in HER2– metastatic breast cancer harboring germline BRCA1/2 mutations.
WU-CART-007 has received RMAT and PRIME designations in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
If you need an omentectomy as a part of your cancer treatment, you probably have a lot of questions. We checked in with gynecologic oncologist…
Generating Evidence for Diverse Populations in Oncology
The FDA has withdrawn the approval for infigratinib to treat patients with cholangiocarcinoma. A phase 3 study comparing it to standard treatment has also been…
Medscape is pleased to present several live symposia in Chicago, Illinois, in June 2024. These in-person and virtual events feature expert panelists who will guide…
Kara Stromberg, MS, RD, LDN, CDCES, was recognized by the Pennsylvania Academy of Nutrition and Dietetics as a Keystone Award winner.
PURPOSE Evidence suggests that oncology patients are satisfied with and sometimes prefer telemedicine compared with in-person visits; however, data are scarce on when telemedicine is…
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Journal of Neuro-Oncology – Current treatment of spinal metastases (SM) aims on preserving spinal stability, neurological status, and functional status as well as achieving local…
In this issue of Blood, Hayashi et al1 assessed the correlation of the level of measurable residual disease (MRD) at the end of induction (EOI) with…